Review
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1632-1647
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1632
Table 1 Overexpression of mammalian target of rapamycin complex 2 and its mediators determine clinical outcome


mTORC2 mediator
Associated with
Measured by
Ref.
Primary liver cancerHCCp-AKTSer473 overexpressionpoor outcome (P < 0.02)IHCHu et al[59]
Rictor overexpressionReduced OS (P = 0.0029)mRNA expressionXu et al[60]
Rictor overexpressionReduced RFS (P = 0.016)IHC, mRNA expressionKaibori et al[61]
iCCCp-AKT1 overexpressionImproved OS (P = 0.0137)IHCLee et al[76]
CRLMData only available for primary CRC
Rictor expressionIncreasing tumor stage mRNA expressionGulhati et al[49]
Rictor expressionIncreasing tumor stageIHC, mRNA expressionShuhua et al[81]
Rictor expressionReduced OS (P = 0.0004)IHCWang et al[10]
Secondary liver cancerBreast cancer liver metastasesData only available for invasive ductal breast carcinoma
Rictor expressionLymph node metastasisIHCZhang et al[90]
Melanoma liver metastasesRictor positivity (primary tumor)Reduced OS (P = 0.018)IHCLiang et al[100]
Rictor expressionTumor stage/metastatic diseasemRNA expressionSchmidt et al[101]
Renal cancer liver metastasesNo data available
Gastric cancer liver metastasesData only available for gastric cancer
Rictor, p-AKTSer437 expressionTumor stage, reduced RFS and OSIHCBian et al[7]
Rictor expressionTumor stage, reduced RFS and OS (P = 0.012, P = 0.014)IHCBian et al[110]
Pancreatic cancer liver metastasesData only available for pancreatic cancer
Rictor expression Reduced OSIHCSchmidt et al[9]